Citations

Showing 10 of 108083 citations.

Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease
Allen, Alina M. , Rowe, Ian A , Allen, Alina M

Mayo Clinic

Hepatology | February 4, 2023 | Volume: 77 | Issue: 6 | Pages: 1843-1845

10.1097/hep.0000000000000327 | PMID 36738088 Get It

Molecular diagnostics for genotypic detection of antibiotic resistance: current landscape and future directions
Banerjee, Ritu , Patel, Robin , Patel, Robin

Mayo Clinic

JAC-Antimicrobial Resistance | February 4, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/jacamr/dlad018 | PMID 36816746 Get It

Abstract Antimicrobial resistance (AMR) among bacteria is an escalating public health emergency that has worsened during the COVID-19 pandemic. When making antibiotic treatment decisions, clinicians rely heavily on determination of antibiotic susceptibility or resistance by the microbiology laboratory, but conventional methods often take several days to identify AMR. There are now several commercially available molecular methods that detect antibiotic resistance genes within hours rather than days. While these methods have limitations, they offer promise for optimizing treatment and patient outcomes, and reducing further emergence of AMR. This review provides an overview of commercially available genotypic assays that detect individual resistance genes and/or resistance-associated mutations in a variety of specimen types and discusses how clinical outcomes studies may be used to demonstrate clinical utility of such diagnostics.
Prognostic value of deep learning based mitotic count in hormonal receptor- and HER2-positive breast cancer
Mercan, Caner , Tessier, Leslie, Tellez, David , Salgado, Roberto , Joensuu, Heikki , Loi, Sherene , Michiels, Stefan , Larsimont, Denis , Wegscheider, Anne-Sophie , Niendorf, Axel, Laak, Jeroen van der , Joensuu, Heikki , Loi, Sherene , Balkenhol, Maschenka C. A. , Sherman, Mark E. , Bult, Peter , Ciompi, Francesco

Mayo Clinic

No container title available | February 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2408990/v1 Get It

Abstract The discovery of molecular subtypes has corroborated the heterogeneity of breast cancers. But in clinical routine, treatment selection relies on measuring the aggressiveness of the tumor via histopathology, which is routinely based on grading, a prognostic yet laborious, poorly reproducible, and subjective procedure defined more than 30 years ago, before molecular subtypes existed. In this paper, we present an interpretable deep learning-based computer-aided diagnosis method to automate mitotic count, one of the components of grading; the method complies with current guidelines and automates hot-spot finding on full digital whole-slide images of routinely prepared pathologic slides stained with hematoxylin and eosin. We use the computer model to query the current “one-size-fits-all” mitotic count procedure by investigating subtype-specific prognostic value of mitotic count using an external independent large-scale multicentric dataset of 1,709 breast cancers. We show that for human epidermal growth factor-2 (HER2) positive tumors, mitotic count was not prognostic. In hormone-receptor positive/HER2 negative cancers, an average mitotic count density different from clinically used cut offs predicted worse recurrence free survival in multivariable analysis, adjusted for known clinical prognosticators. We provided some first experimental evidence that the prognostic role of mitotic count should be reviewed.
Equity360: Gender, Race, and Ethnicity—All Orthopaedic Surgeon Burnout Is Not Created Equal
Lajam, Claudette M. , O’Connor, Mary I.

Mayo Clinic

Clinical Orthopaedics & Related Research | February 3, 2023 | Volume: 481 | Issue: 3 | Pages: 451-454

10.1097/corr.0000000000002574 | PMID 36735584 Get It

Association Between Perioperative Costs and Induction Immunosuppression in Pediatric Liver Transplant Recipients
Ewing, Caroline , Farnan, Sheila, Squires, James E. , Squires, James E , Raghu, Vikram Kalathur

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 3, 2023 | Volume: 76 | Issue: 5 | Pages: 634-639

10.1097/mpg.0000000000003728 | PMID 36735593 Get It

Objectives:The objectives of this study was to describe variation in induction regimen, identify predictors of induction immunosuppression (IS) choice, and examine the impact of induction IS regimen on length of stay (LOS) and total perioperative costs in pediatric liver transplant recipients.Methods:We analyzed liver transplant utilization data in the Pediatric Health Information System database. Patients were divided into 3 induction IS groups: (1) steroids only, (2) T‐cell depleting antibody (TDA), and (3) non‐TDA. We identified predictors of induction IS regimen and examined associations between each outcome and choice of induction IS.Results:We analyzed 4905 liver transplant recipients (50% female, 80% under age 13 years, 42% non‐Hispanic White). Most patients (3162, 64%) received steroids only induction, and about twice as many patients received a non‐TDA regimen (1093, 22%) versus a TDA regimen (650, 13%). Median total perioperative costs were highest for the TDA group [$146,438 (interquartile range $113,461–$195,575)] versus the non‐TDA group [$129,307 ($102,632–$173,953)] and the steroids only group ($127,049 ($98,814–$181,053)]. Compared to steroids only induction, TDA was associated with increased LOS (+2 days, P = 0.017) with no difference in cost. Non‐TDA induction was associated with a decreased LOS (−3 days, P < 0.001) and increased cost (+$42,542; P < 0.001) independent of LOS.Conclusions:Compared to a steroids only induction IS regimen, non‐TDA induction was associated with increased total perioperative costs, even after adjustments for LOS. Future work will combine cost and outcome data to provide decision‐making support in pediatric liver transplant recipients.
Closing the window on COVID-19 case-control studies
Dillon, Gabrielle A. , Joyner, Michael J. , Baker, Sarah E. , Ranadive, Sushant M. , Joyner, Michael J , Baker, Sarah E

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | February 3, 2023 | Volume: 324 | Issue: 3 | Pages: H364-H365

10.1152/ajpheart.00048.2023 | PMID 36735404 Get It

Imaging of Bifid Fourth Rib Presenting as a Chest Wall Mass in an Infant
Garg, Pankaj , Ahmed, Magdy M. El‐Sayed , Garg, Pankaj

Mayo Clinic

Texas Heart Institute Journal | February 3, 2023 | Volume: 50 | Issue: 1 | Pages: No page available

10.14503/thij-22-7975 | PMID 36735608 Get It

Triphasic response after endoscopic craniopharyngioma resection and its dependency on infundibular preservation or sacrifice
Lopez, Diana C., Andrade, Erion Júnior de , Yogi-Morren, Divya , Kshettry, Varun R. , Almeida, João Paulo , Momin, Arbaz A. , Soni, Pranay , Recinos, Pablo F.

Mayo Clinic

Journal of Neurosurgery | February 3, 2023 | Volume: 139 | Issue: 3 | Pages: 790-797

10.3171/2022.12.jns221137 | PMID 36738460 Get It

OBJECTIVE Surgery is the primary treatment for craniopharyngioma with the preservation of hypothalamic function of paramount importance. Infundibular preservation is debated, as maximal resection decreases recurrence rates but causes hypopituitarism. A triphasic response of diabetes insipidus (DI), syndrome of inappropriate antidiuretic hormone secretion (SIADH), and recurrent DI has been described after pituitary surgery, but the impact of infundibular preservation on the triphasic response following craniopharyngioma resection has not been well established. The authors’ objective was to assess postoperative fluid and sodium balance and differences in ADH imbalance management following endonasal craniopharyngioma resection based on infundibular transection status. METHODS This is a retrospective cohort study of 19 patients with craniopharyngioma treated with endoscopic endonasal resection between 2014 and 2021. Resection was dichotomized into infundibular transection or preservation. Postoperative triphasic response, time to DI, and time to ADH replacement were compared using Fisher’s exact test and Kaplan-Meier analysis. RESULTS Based on surgeon impression, 10 patients had infundibular transection and 9 had infundibular preservation. Overall, 16 patients experienced DI, 12 experienced persistent DI, and 6 experienced SIADH. A postoperative triphasic response occurred in 40% (n = 4) of transection patients without preoperative DI and 11% (n = 1) of preservation patients without preoperative DI. The median time to postoperative DI (0.5 vs 18.0 hours, p = 0.022) and median time to ADH replacement therapy (4.5 vs 24 hours, p = 0.0004) were significantly shorter in the transection group than in the preservation group. CONCLUSIONS Following endonasal craniopharyngioma resection, the triphasic response occurs in nearly half of infundibular transection cases. DI begins earlier with infundibular transection. On the basis of the study findings in which no patients met the criteria for SIADH or were endocrinologically unstable after postoperative day 6, it is reasonable to suggest that otherwise stable patients can be discharged at or before postoperative day 6 when ADH fluctuations have normalized and endocrinopathy is appropriately managed with oral desmopressin. Infundibular transection status may impact postoperative hormonal replacement strategies, but additional studies should evaluate their efficacies.
Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010
Garcia‐Arango, Mariana , Dasari, Harika , Calle, Maria Arciniegas, Adjei, Effie, Mesa, Juan Rico, Thompson, Carrie A. , Haddad, Tufia C. , Herrmann, Joerg , Villarraga, Hector R. , Larsen, Carolyn M , Garcia Arango, Mariana, Arciniegas Calle, Maria, Rico Mesa, Juan, Larsen, Carolyn , Scott, Christopher G. , Cerhan, James R. , Goetz, Matthew P.

Mayo Clinic

JAMA Network Open | February 3, 2023 | Volume: 6 | Issue: 2 | Pages: e2254669

10.1001/jamanetworkopen.2022.54669 | PMID 36735254 Get It

ImportanceAnthracyclines increase the risk for congestive heart failure (CHF); however, long-term cumulative incidence and risk factors for CHF after anthracycline therapy are not well defined in population-based studies.ObjectiveTo compare the long-term cumulative incidence of CHF in patients with breast cancer or lymphoma treated with anthracycline therapy compared with healthy controls from the same community.Design, Setting, and ParticipantsThis retrospective population-based case-control study included data from the Rochester Epidemiology Project. Participants included residents of Olmsted County, Minnesota, diagnosed with breast cancer or lymphoma from January 1985 through December 2010 matched for age, sex, and comorbidities with healthy controls, with a final ratio of 1 case to 1.5 controls. Statistical analysis was performed between July 2017 and February 2022.ExposuresCancer treatment and CHF risk factors.Main Outcomes and MeasuresThe main outcome was new-onset CHF, as defined by the modified Framingham criteria. Cox proportional hazards regression was used to estimate hazard ratios (HRs) to compare the risk of CHF in participants with cancer vs controls, adjusted for age, sex, diabetes, hypertension, hyperlipidemia, coronary artery disease, obesity, and smoking history.ResultsA total of 2196 individuals were included, with 812 patients with cancer and 1384 participants without cancer. The mean (SD) age was 52.62 (14.56) years and 1704 participants (78%) were female. Median (IQR) follow-up was 8.6 (5.2-13.4) years in the case group vs 12.5 (8.7-17.5) years in the control group. Overall, patients with cancer had higher risk of CHF compared with the control cohort even after adjusting for age, sex, diabetes, hypertension, coronary artery disease, hyperlipidemia, obesity, and smoking status (HR, 2.86 [95% CI, 1.90-4.32]; P &amp;lt; .001). After adjusting for the same variables, CHF risk was greater for patients with cancer receiving anthracycline (HR, 3.25 [95% CI, 2.11-5.00]; P &amp;lt; .001) and was attenuated and lost statistical significance for patients with cancer not receiving anthracyclines (HR, 1.78 [95% CI, 0.83-3.81]; P = .14). Higher cumulative incidence for patients treated with anthracyclines vs comparator cohort was observed at 1 year (1.81% vs 0.09%), 5 years (2.91% vs 0.79%), 10 years (5.36% vs 1.74%), 15 years (7.42% vs 3.18%), and 20 years (10.75% vs 4.98%) (P &amp;lt; .001). There were no significant differences in risk of CHF for patients receiving anthracycline at a dose of less than 180 mg/m2 compared with those at a dose of 180 to 250 mg/m2 (HR, 0.54 [95% CI, 0.19-1.51]) or at a dose of more than 250 mg/m2 (HR, 1.23 [95% CI, 0.52-2.91]). At diagnosis, age was an independent risk factor associated with CHF (HR per 10 years, 2.77 [95% CI, 1.99-3.86]; P &amp;lt; .001).Conclusions and RelevanceIn this retrospective population-based case-control study, anthracyclines were associated with an increased risk of CHF early during follow-up, and the increased risk persisted over time. The cumulative incidence of CHF in patients with breast cancer or lymphoma treated with anthracyclines at 15 years was more than 2-fold that of the control group.